Key Takeaways
- • Spyre Therapeutics' SPY072 failed to meet the company's internal efficacy bar in Phase 2 SKYWAY rheumatoid arthritis trials, prompting the decision not to prioritize RA monotherapy development despite statistically significant results on the primary endpoint.
- • Stock declined 12.33% to $94.12 following the announcement, with after-hours trading showing further weakness as investors reassessed the TL1A antibody candidate's commercial trajectory.
- • SPY072 demonstrated complete target engagement with full, durable suppression of free TL1A through 12 weeks and a favorable safety profile (27% adverse event rate vs. 36% placebo), but efficacy magnitude fell short of internal advancement criteria.
- • The company will redirect focus toward combination therapy strategies and other indications, with Phase 2 topline data expected in psoriatic arthritis and axial spondyloarthritis by Q4 2026, and SPY072 combined with IL-17A/F in hidradenitis suppurativa in late 2027 or early 2028.
- • Results demonstrate clinical proof-of-concept for the TL1A mechanism but signal that monotherapy efficacy in RA may be insufficient, shifting strategic emphasis toward multi-drug combinations in autoimmune disorders.
Summary
Spyre Therapeutics announced topline results from the rheumatoid arthritis sub-study of its Phase 2 SKYWAY trial for SPY072 on Tuesday, revealing a clinical outcome that, while statistically significant, failed to clear the company's internal prioritization threshold for advancing the TL1A antibody as a monotherapy in RA. The disclosure triggered a sharp equity decline, with shares trading down 12.33% to $94.12 by Wednesday market open, with after-hours trading reflecting additional pressure as institutional investors reassessed the near-term development pathway.
The trial data presented a clinically mixed picture. SPY072 achieved statistical significance on the primary endpoint—change from baseline in DAS28-CRP at Week 12—across the low-dose cohort and demonstrated complete, durable suppression of free TL1A through 12 weeks, confirming robust target engagement. The high dose produced nominally significant improvements on the secondary ACR20 endpoint, while the low dose achieved exploratory ACR50 success. Critically, the safety profile aligned with TL1A class expectations, with the treatment arm recording adverse events at 27%, notably lower than the 36% rate observed in the placebo group. Efficacy was comparable between therapy-naïve patients and those with prior advanced therapy exposure, suggesting consistent mechanism performance across patient populations.
Despite these favorable mechanistic and safety signals, Spyre determined that the efficacy magnitude did not justify prioritizing SPY072 as a monotherapy in RA under its internal development framework. Rather than abandoning the program entirely, the company is pivoting toward combination therapy strategies and expanding evaluation into alternative indications. Topline data for SPY072 in psoriatic arthritis and axial spondyloarthritis are expected by Q4 2026, while combination trials pairing SPY072 with IL-17A/F in hidradenitis suppurativa are projected to yield data in late 2027 or early 2028.
The outcome underscores a persistent challenge in autoimmune drug development: demonstrating sufficient clinical differentiation in saturated markets where standard-of-care therapies are well-established and efficacious. For Spyre, the TL1A mechanism has now established proof-of-concept, positioning the company to explore whether combination approaches or disease adjacencies—particularly in IL-17 responsive conditions—may unlock greater commercial and clinical value than RA monotherapy alone.
The trial data presented a clinically mixed picture. SPY072 achieved statistical significance on the primary endpoint—change from baseline in DAS28-CRP at Week 12—across the low-dose cohort and demonstrated complete, durable suppression of free TL1A through 12 weeks, confirming robust target engagement. The high dose produced nominally significant improvements on the secondary ACR20 endpoint, while the low dose achieved exploratory ACR50 success. Critically, the safety profile aligned with TL1A class expectations, with the treatment arm recording adverse events at 27%, notably lower than the 36% rate observed in the placebo group. Efficacy was comparable between therapy-naïve patients and those with prior advanced therapy exposure, suggesting consistent mechanism performance across patient populations.
Despite these favorable mechanistic and safety signals, Spyre determined that the efficacy magnitude did not justify prioritizing SPY072 as a monotherapy in RA under its internal development framework. Rather than abandoning the program entirely, the company is pivoting toward combination therapy strategies and expanding evaluation into alternative indications. Topline data for SPY072 in psoriatic arthritis and axial spondyloarthritis are expected by Q4 2026, while combination trials pairing SPY072 with IL-17A/F in hidradenitis suppurativa are projected to yield data in late 2027 or early 2028.
The outcome underscores a persistent challenge in autoimmune drug development: demonstrating sufficient clinical differentiation in saturated markets where standard-of-care therapies are well-established and efficacious. For Spyre, the TL1A mechanism has now established proof-of-concept, positioning the company to explore whether combination approaches or disease adjacencies—particularly in IL-17 responsive conditions—may unlock greater commercial and clinical value than RA monotherapy alone.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.